Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd. reports developments for a medical technology company focused on physical rehabilitation and recovery. Its product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit, with use in clinical settings and in home or community rehabilitation.
Company news covers financial results, access initiatives for the FDA-cleared ReWalk Personal Exoskeleton, collaborations with rehabilitation providers, and regulatory or clinical disclosures tied to rehabilitation technologies. Other recurring updates address Nasdaq listing compliance, shareholder voting matters, governance changes, material agreements, acquisitions, and capital-structure actions involving ordinary shares and warrants.
Lifeward (Nasdaq: LFWD) reported Q4 and full‑year 2025 results and announced a shareholder‑approved strategic transaction with Oramed that transfers the POD™ oral protein delivery platform to Lifeward and could provide up to $47 million in funding.
2025 revenue was $22.0M, net loss $19.9M, GAAP operating expenses fell 25%, and unrestricted cash was $2.2M. Lifeward also agreed to acquire an upper‑body exoskeleton and secured expanded U.S. Medicare Advantage reimbursement for ReWalk.
Lifeward (Nasdaq: LFWD) received shareholder approval to close a strategic partnership with Oramed (Nasdaq: ORMP) that integrates Oramed’s POD™ oral protein delivery platform into Lifeward while Oramed acquires a significant equity stake.
The structure provides Lifeward potential access to up to $47 million, keeps Oramed responsible for POD™ clinical funding, and aims to combine near‑term MedTech profitability with long‑term biotech upside.
Lifeward (Nasdaq: LFWD) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, a condition satisfied on March 9, 2026. The Nasdaq Listing Qualifications Staff considers the prior bid price deficiency closed and Lifeward ordinary shares will continue trading on The Nasdaq Capital Market.
Lifeward (Nasdaq: LFWD) will report fourth quarter and full year 2025 financial results before markets open on March 18, 2026. A live conference call and webcast with CEO Mark Grant and CFO Almog Adar begins at 8:30 a.m. EST. An archived webcast will be available on the Investors Events Calendar.
Lifeward (Nasdaq: LFWD) announced a collaboration with Shirley Ryan AbilityLab to launch dedicated clinic days in Q2 2026 to accelerate evaluation and access to the ReWalk Personal Exoskeleton for people with spinal cord injury (SCI).
Shirley Ryan AbilityLab will lead clinical evaluation, training and patient support, while Lifeward provides ReWalk, an FDA-cleared wearable robotic system enabling standing, walking, and navigation of stairs and curbs.
Lifeward (Nasdaq: LFWD) agreed to acquire upper-body exoskeleton technology and prototypes from Skelable for $480,000 in Lifeward equity plus a nominal cash payment, with the Skelable engineering team joining Lifeward.
The device targets post-stroke upper-limb rehabilitation; Lifeward expects commercial readiness in ~18–24 months following development and regulatory approvals.
Lifeward (Nasdaq: LFWD) will effect a 1-for-12 reverse share split effective at market open on February 24, 2026, combining every twelve issued ordinary shares into one share and assigning a new CUSIP (M8216Q309).
The Board also increased authorized share capital to 100,000,000 shares. The company expects shares outstanding to fall from ~18.3 million pre-split to ~1.5 million post-split and says the move aims to meet Nasdaq's $1.00 bid-price continued listing standard.
Lifeward (Nasdaq: LFWD) announced on Feb 17, 2026 that Aetna issued a prior authorization for a Medicare Advantage beneficiary to obtain the ReWalk Personal Exoskeleton, joining Humana and UnitedHealthcare.
Coverage now spans three major Medicare Advantage insurers, representing approximately 16 million beneficiaries, for qualified individuals meeting medical necessity criteria.
The ReWalk Personal Exoskeleton is FDA-approved; peer-reviewed studies cited benefits for ambulation, musculoskeletal health, and cardiopulmonary function.
Lifeward (Nasdaq: LFWD) entered a strategic partnership with Oramed (Nasdaq: ORMP) under which Lifeward will acquire Oramed's clinical-stage POD™ protein oral delivery platform and Oramed may acquire up to 49.99% of Lifeward. The transaction provides Lifeward access to up to $47 million via equity, convertible notes, milestone funding and warrants, and includes Oramed funding and managing planned POD™ clinical work.
The deal includes a 4% net-sales royalty on ReWalk for up to 10 years and preserves Lifeward’s focus on achieving cash‑flow profitability while adding biotech upside tied to oral insulin and other protein therapies.
Oramed Pharmaceuticals and Lifeward (NASDAQ: LFWD) signed binding agreements dated January 13, 2026 to transfer Oramed's POD™ oral drug delivery platform to Lifeward in exchange for Oramed receiving a 49.9% beneficial ownership interest upon satisfaction of closing conditions. Lifeward will issue two $10 million senior secured convertible notes (8% interest) with 100% warrant coverage; Oramed to invest $9M in each note. Oramed will fund and manage the upcoming clinical trial and receive 4% of net ReWalk sales for up to 10 years. Lifeward reported $26M revenue from ReWalk and AlterG in the last four quarters.